Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Staar Surgical CoSTAA -10.16%83 Debt-to-EBITDA is 0.48 as of Mar. 2026, which is 20% below its 10-year median of 0.60. GuruFocus rates STAA with a GF Score™ of 83/100 and a GF Value™ of $32.05 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Staar Surgical Co ranks worse than 64.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Staar Surgical Co's Debt-to-EBITDA or its related term are showing as below:
STAA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -22.55 Med: 0.6 Max: 2.53
Current: 2.53
During the past 13 years, the highest Debt-to-EBITDA Ratio of Staar Surgical Co was 2.53. The lowest was -22.55. And the median was 0.60.
STAA's Debt-to-EBITDA is ranked worse than 64.39% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs STAA: 2.53
Staar Surgical Co (NAS:STAA) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Staar Surgical Co Debt-to-EBITDA Related Terms
Staar Surgical Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Staar Surgical Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STAA vs BLFS, ATRC, KMTS: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Staar Surgical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Staar Surgical Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Staar Surgical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Staar Surgical Co (STAA) has a Debt-to-EBITDA of 0.48 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Staar Surgical Co. This is 20% below median its historical median of 0.60. According to the industry distribution chart, Staar Surgical Co ranks #302 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 64.4%.
Is Staar Surgical Co's Debt-to-EBITDA too high?
Staar Surgical Co's current Debt-to-EBITDA of 0.48 is 20% below median its 10-year median of 0.60. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Staar Surgical Co's value of 0.48 is 70% below this industry median. Based on the distribution chart, Staar Surgical Co ranks #302 out of 469 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Staar Surgical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Staar Surgical Co's Debt-to-EBITDA compare to BLFS and ATRC?
According to the Medical Devices & Instruments industry distribution chart, Staar Surgical Co ranks #302 out of 469 companies for Debt-to-EBITDA. This places Staar Surgical Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. Staar Surgical Co's value of 0.48 is 70% below this benchmark. While the company's 10-year median is 0.60 vs. the industry median of 1.60, Staar Surgical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Staar Surgical Co's current Debt-to-EBITDA of 0.48 is 70% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Staar Surgical Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Staar Surgical Co's current Debt-to-EBITDA is 0.48, which is 20% below median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staar Surgical Co stock overvalued right now?
Based on GuruFocus' analysis, Staar Surgical Co (STAA) is currently considered Modestly Undervalued. The stock's GF Value™ is $32.05, compared to a current price of $26.05 — trading 18.7% below its estimated fair value. The current Debt-to-EBITDA is 0.48, which is 20% below median its 10-year median of 0.60 and 70% below the Medical Devices & Instruments industry median of 1.60. Staar Surgical Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Staar Surgical Co (STAA), the current Debt-to-EBITDA is 0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Staar Surgical Co (STAA) Overvalued in 2026?
Based on GuruFocus' analysis, Staar Surgical Co stock appears to be undervalued.
The current stock price of $26.05 is trading 18.7% below its estimated GF Value™ of $32.05.
GuruFocus considers Staar Surgical Co to be Modestly Undervalued.
Key valuation signals for STAA:
Debt-to-EBITDA: 0.48 (20% below median its 10-year median of 0.60)
GF Value™: $32.05 vs. price of $26.05 (18.7% below fair value)
Industry Position: 70% below the Medical Devices & Instruments median (#302 of 469)
No single metric tells the full story. See the STAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
83GF Score
Get the complete analysis for STAA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STAA has been successfully added to your 
